Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen and Erasmus University Medical Center Rotterdam have extended their alliance by concluding a collaboration agreement to identify and progress therapeutics within the fields of endocrinology, diabetes and metabolism.
Subscribe to our email newsletter
Accordingly, Ipsen and Erasmus Research Institute for Neuroendocrinology research teams will meet regularly to identify new therapeutic opportunities leading to novel pharmaceutical compounds, or the identification of novel indications for products marketed in endocrinology.
The parties will identify and validate targets of mutual interest and test compounds in order to produce lead candidates for further development. All joint inventions will be owned by Erasmus University Medical Center Rotterdam (Erasmus MC) with Ipsen having an exclusive option to license and commercialize these inventions.
Jacques-Pierre Moreau, executive vice president and chief scientific officer of Ipsen, said: “Erasmus MC is one of the leading academic centers in the treatment of endocrine diseases. Thus, it is gratifying for Ipsen to have the opportunity to be associated with a group of world-class scientists with whom we intend to collaborate closely in the search for novel therapeutic concepts and products for the treatment of endocrine conditions such as diabetes and obesity which are rapidly becoming a world pandemic.”